Médecine

Paramédical

Autres domaines


S'abonner

Super-Minimalist Immediate Mechanical Intervention (Super-MIMI) study - 10/11/15

Doi : 10.1016/j.ancard.2015.09.007 
L. Belle 1, , H. Madiot 1, H. Bouvaist 1, N. Delarche 2, F. Bouisset 3, P.-Y. Petiteau 4, Z. Boueri 5, M. Bdellaoui 6, C. Durier 7, O. Dubreuil 8
1 Cardiology department, CH Annecy, 74370 Pringy, France 
2 Cardiology department, CH Pau, 64000 Pau, France 
3 Cardiology department, CHU de Toulouse, 31400 Toulouse, France 
4 Cardiology department, Clinique Saint-Vincent, 25000 Besançon, France 
5 Cardiology department, CH Bastia, 20600 Bastia, France 
6 Cardiology department, GHM Grenoble, 38000 Grenoble, France 
7 Cardiology department, CH Argenteuil, 95107 Argenteuil, France 
8 Cardiology department, Clinic Saint-Joseph-Saint-Luc, 69000 Lyon, France 

Corresponding author.

Résumé

Purpose

To evaluate the safety of extended-delay stenting (>7days between procedures) in the setting of percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI).

Methods

This ongoing prospective observational study is being conducted in STEMI patients with a high thrombus burden in the infarct-related artery (IRA). Patients are enrolled if the operator decides to try to restore the best TIMI flow with the thinnest tool (i.e. wire, aspiration, or thin balloon) and defer stent implantation for>7days under optimal anticoagulation to reduce thrombus burden. The primary endpoint is the composite of reocclusion of the IRA or sudden death between the two procedures, and deterioration of the flow (from the final flow achieved after the first procedure to the initial flow at the second procedure).

Results

Between January 2014 and January 2015, 127 patients (of 135 we will enroll) were enrolled at 14 centres: 110 were men and the mean age±SD was 57.1±13.0years. Ninety-eight patients underwent a primary PCI as the first procedure and 29 patients underwent PCI after fibrinolysis. The final TIMI flow at the first procedure was 3 in 119 patients, 2 in 7 patients, and 1 in 1 patient. This final flow was spontaneous (same as initial flow, in the absence of intervention) in 43 patients, and after wire in 3 patients, thrombus aspiration in 60, and with a 1.5–2.5mm diameter balloon in 21 patients. At the end of the first PCI, the residual culprit lesion was 61±24%. Aspirin, P2Y12 inhibitors, and anticoagulants were used in all patients between the two procedures, and a glycoprotein IIb/IIIa inhibitor in 42 patients. The second procedure was performed between 7 and 26days after the first. None of the patients died between the two procedures; 1 patient experienced a reocclusion of the IRA 15min after the first procedure. In all cases, initial TIMI flow in the IRA (at the start of the second procedure) was the same as or better than the final flow after the first procedure. A stent was implanted in 80 patients, whereas no significant lesion was documented in 47 patients. Final results will be presented at the meeting.

Conclusions

In PCI for acute STEMI, when the thrombus burden is high, stenting delayed by 7–26days with intensive antithrombotic cover appears safe, with only 1 of 127 patients developing an IRA reocclusion.

Le texte complet de cet article est disponible en PDF.

Plan


© 2015  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 64 - N° 5

P. 416 - novembre 2015 Retour au numéro
Article précédent Article précédent
  • Reperfusion in elderly patients with acute ST-elevation myocardial infarction: Results from the RENAU-RESURCOR STEMI network
  • J. Turk, M. Fourny, G. Debaty, J. Labarere, M. Rata, K. Yayehd, A. Ispas, G. Deschanel, M. Latappy, L. Belle
| Article suivant Article suivant
  • Incidence of radiation-induced skin lesions after percutaneous coronary intervention
  • A. Paziuc, L. Mangin, A. Ispas, M. Ra??, B. Lafitte, H. Madiot, S. Vanwalleghem, C. Ricard, J.-L. Georges, L. Belle

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.